SanBio Co (JP:4592) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
SanBio Co., Ltd. has announced that the US Patent and Trademark Office has granted a Notice of Allowance for a new patent application for SB623, a cell therapy for treating chronic ischemic stroke with smaller infarctions. The patent was backed by positive results from a Phase 2b clinical trial showing significant improvement in patients treated with SB623 compared to a control group. This advancement is expected to bolster the company’s patent portfolio and extend the use patent of SB623 in the US, the largest market for such treatments.
For further insights into JP:4592 stock, check out TipRanks’ Stock Analysis page.
